natgillin/translations-raw huggingface dataset:
Xadago must not be administered along with other MAO inhibitors (including moclobemide) as there may be a risk of non-selective MAO inhibition that may lead to a hypertensive crisis (see section 4.3).
Xadago se ne smije primjenjivati zajedno s drugim MAO inhibitorima (uključujući moklobemid), jer može postojati rizik od neselektivne MAO inhibicije koja može dovesti do hipertenzivne krize (vidjeti dio 4.3).
Xadago should be taken with water.
Xadago je potrebno uzeti s vodom.
Xadago should not be administered to patients with ophthalmological history that would put them at increased risk for potential retinal effects (e.g., albino patients, family history of hereditary retinal disease, retinitis pigmentosa, any active retinopathy, or uveitis) see section 4.3 and 5.3.
Xadago se ne smije primjenjivati u bolesnika s oftalmološkom poviješću koja bi u njih povećala rizik za mogući učinak na mrežnicu (npr. albino bolesnici, obiteljska povijest nasljedne bolesti mrežnice, retinitis pigmentosa, bilo koja aktivna retinopatija ili uveitis) vidjeti dio 4.3. i 5.3.
Xadago should not be given during pregnancy.
Xadago se ne smije davati tijekom trudnoće.
Xadago should not be given to breast-feeding women.
Xadago se ne smije davati dojiljama.
Xadago should not be given to women of childbearing potential unless adequate contraception is practiced.
Xadago se ne smije davati ženama u reproduktivnoj dobi osim ako se koristi odgovarajuća kontracepcija.
Xadago use in patients with severe hepatic impairment is contraindicated (see section 4.3).
Kontraindicirana je primjena lijeka Xadago u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
Xadago was also investigated as an add-on to treatment in 2 studies in patients with early Parkinson’s disease without fluctuations, but these studies did not show a clear benefit and the company did not pursue this use as part of the application.
Xadago je također ispitan kao dodatna terapija u 2 ispitivanja u bolesnika s ranom Parkinsonovom bolesti bez fluktuacija, no ovim ispitivanjima nije utvrđena jasna korist,a tvrtka nije zatražila odobrenje za ovu primjenu u sklopu prijave.
Xadago, as an add-on treatment to levodopa with or without other medicines for Parkinson’s disease, has been compared with placebo (a dummy treatment) in two main studies involving 1,218 patients with late stage Parkinson’s disease who experienced fluctuations.
Xadago, kao dodatna terapija uz levodop s ili bez drugih lijekova za Parkinsonovu bolest, uspoređen je s placebom (lažnim liječenjem) u dva glavna ispitivanja koja su obuhvatila 1218 bolesnika s Parkinsonovom bolesti u kasnoj fazi, a koji su imali fluktuacije.
Xagrid (on the outer carton only)
Xagrid (samo na vanjskoj kutiji)
Xagrid 0.5 mg hard capsules anagrelide
Xagrid 0,5 mg tvrde kapsule anagrelid
Xagrid 0.5 mg hard capsules.
Xagrid 0,5 mg tvrde kapsule.
Xagrid anagrelide
Xagrid anagrelid
Xagrid has been authorised under ‘exceptional circumstances’.
Xagrid je odobren u „iznimnim okolnostima”.
Xagrid has been studied in four main studies involving patients with various diseases in which the bone marrow produces too many cells.
Xagrid je ispitivan u okviru četiriju glavnih studija na bolesnicima s raznim bolestima pri kojima koštana srž proizvodi previše stanica.
Xagrid is a medicine that contains the active substance anagrelide.
Xagrid je lijek koji sadrži djelatnu tvar anagrelid.
Xagrid was effective in lowering platelet counts.
Xagrid se pokazao učinkovitim u smanjenju broja trombocita.
Xagrid was not compared with any other medicines.
Xagrid nije uspoređivan niti s jednim drugim lijekom.
XALKORI 200 mg hard capsules Crizotinib
XALKORI 200 mg tvrde kapsule krizotinib
XALKORI 200 mg hard capsules XALKORI 250 mg hard capsules
XALKORI 200 mg tvrde kapsule XALKORI 250 mg tvrde kapsule
XALKORI 200 mg hard capsules XALKORI 250 mg hard capsules Crizotinib
XALKORI 200 mg tvrde kapsule XALKORI 250 mg tvrde kapsule krizotinib
XALKORI 200 mg is supplied as hard gelatin capsules with pink cap and white body, printed with black ink “Pfizer” on the cap, “CRZ 200” on the body.
XALKORI 200 mg su tvrde želatinske kapsule s ružičastom kapicom i bijelim tijelom, s crno otisnutom oznakom "Pfizer" na kapici i "CRZ 200" na tijelu.
XALKORI 250 mg hard capsules Crizotinib
XALKORI 250 mg tvrde kapsule krizotinib
XALKORI 250 mg hard capsules EU/1/12/793/003 EU/1/12/793/004
XALKORI 250 mg tvrde kapsule EU/1/12/793/003 EU/1/12/793/004
Xalkori has been given ‘conditional approval’.
Za lijek Xalkori izdano je „uvjetno odobrenje”.
Xalkori is a medicine that contains the active substance crizotinib.
Xalkori je lijek koji sadrži djelatnu tvar krizotinib.
XALKORI is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
XALKORI je indiciran u prvoj liniji liječenja odraslih bolesnika s uznapredovalim rakom pluća nemalih stanica (engl. non-small cell lung cancer, NSCLC), pozitivnim na kinazu anaplastičnog limfoma (engl. anaplastic lymphoma kinase, ALK).
XALKORI is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
XALKORI je indiciran za liječenje odraslih bolesnika s prethodno liječenim uznapredovalim rakom pluća nemalih stanica (engl. non-small cell lung cancer, NSCLC), pozitivnim na kinazu anaplastičnog limfoma (engl. anaplastic lymphoma kinase, ALK).
XALKORI is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).
XALKORI je indiciran za liječenje odraslih s ROS1-pozitivnim uznapredovalim rakom pluća nemalih stanica (NSCLC).
Xalkori is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC), when the disease is advanced.
Xalkori se koristi za liječenje odraslih osoba oboljelih od raka pluća nemalih stanica (NSCLC), u slučajevima kada je bolest uznapredovala.
XALKORI may cause hepatotoxicity, symptomatic bradycardia (e.g., syncope, dizziness, hypotension), interstitial lung disease/pneumonitis, neutropenia and leukopenia, renal cyst, oedema, neuropathy, and reproductive toxicity.
XALKORI može uzrokovati hepatotoksičnost, simptomatsku bradikardiju (npr. sinkopu, omaglicu, hipotenziju), intersticijsku bolest pluća/pneumonitis i neutropeniju i leukopeniju, bubrežnu cistu, edem, neuropatiju i reproduktivnu toksičnost.
XALKORI must be permanently discontinued in case of further Grade ≥3 recurrence.
Primjena lijeka XALKORI mora se trajno obustaviti u slučaju ponovne pojave toksičnosti stupnja ≥3.
Xalkori must not be used in patients with severely reduced liver function.
Lijek Xalkori ne smiju uzimati bolesnici s ozbiljno smanjenom funkcijom jetre.
Xalkori was also investigated in one study in 53 ROS1-positive patients with advanced disease.
Xalkori je također ispitivan u jednom ispitivanju s 53 ROS1-pozitivna bolesnika u kojih je bolest uznapredovala.
Xalkori was investigated in patients with ALK-positive NSCLC who had been treated before with other cancer medicines.
Xalkori je ispitivan u bolesnika s ALK-pozitivnim NSCLC-om koji su prethodno liječeni drugim lijekovima protiv raka.
Xaluprine 20 mg/ml oral suspension
Xaluprine 20 mg/ml oralna suspenzija
Xaluprine contains aspartame, sodium methyl parahydroxybenzoate (E219), sodium ethyl parahydroxybenzoate (E215)
Xaluprine sadrži aspartam, natrijev metilparahidroksibenzoat (E219), natrijev etilparahidroksibenzoat (E215)
Xaluprine contains mercaptopurine.
Xaluprine sadrži merkaptopurin.
Xaluprine is a pink to brown oral suspension.
Xaluprine je ružičasta do smeđa oralna suspenzija.
Xaluprine may be taken with food or on an empty stomach.
Xaluprine se može uzimati s hranom ili natašte.
Xaluprine may harm your sperm or eggs (see ‘Pregnancy, breast-feeding and fertility’ below).
Xaluprine može oštetiti vašu spermu ili jajašca (pogledajte „Trudnoća, dojenje i plodnost“ u nastavku).
Xaluprine should be taken at least 1 hour before or 2 hours after milk or dairy products.
Xaluprine je potrebno uzeti najmanje sat vremena prije ili 2 sata nakon konzumiranja mlijeka ili mliječnih proizvoda.
Xaluprine should not be handled by women who are or planning to be pregnant or breastfeeding.
Xaluprine ne bi smjele uzimati žene koje planiraju zatrudnjeti ili dojiti.
Xaluprine treatment should be supervised by a physician or other healthcare professional experienced in the management of patients with ALL.
Liječenje Xaluprinom treba nadzirati liječnik ili drugi zdravstveni djelatnik iskusan u liječenju bolesnika s ALL-om.
Xaluprine with food and drink
Xaluprine s hranom i pićem
Xanthan gum
Ksantanska guma
Xanthine oxidase is the main catabolic enzyme and it converts the 6–mercaptopurine into the inactive metabolite, 6-thiouric acid.
Ksantin oksidaza je glavni katabolički enzim koji pretvara 6-merkaptopurin u inaktivni metabolit, 6-tiouričnu kiselinu.
Xarelto
Terapijska doza
Xarelto 10 mg film-coated tablets
Xarelto 10 mg filmom obložene tablete
Xarelto 10 mg film-coated tablets are light red, round, biconvex and marked with the BAYER-cross on one side and "10" and a triangle on the other side.
Xarelto 10 mg filmom obložene tablete su svijetlocrvene boje, okrugle, bikonveksne i označene s BAYER-ovim križićem na jednoj strani, te brojem „10“ i trokutom na drugoj strani.
Xarelto 10 mg tablets rivaroxaban
Xarelto 10 mg tablete rivaroksaban
Xarelto 15 mg (only applicable for outer carton, not applicable for bottle label)
Xarelto 15 mg (primjenjivo samo za vanjsku kutiju, nije primjenjivo za etiketu za bocu)
Xarelto 15 mg and 20 mg are to be taken with food (see section 4.2).
Xarelto tablete od 15 i 20 mg moraju se uzimati s hranom (vidjeti dio 4.2.).
Xarelto 15 mg film-coated tablets
Xarelto 15 mg filmom obložene tablete
Xarelto 15 mg film-coated tablets are red, round, biconvex and marked with the BAYER-cross on one side and “15” and a triangle on the other side.
Xarelto 15 mg filmom obložene tablete su crvene, okrugle, bikonveksne tablete označene s BAYER- ovim križićem na jednoj strani, te brojem "15" i trokutom na drugoj strani.
Xarelto 15 mg film-coated tablets are red, round, biconvex and marked with the BAYER-cross on one side and “15” and a triangle on the other side.
Xarelto 15 mg filmom obložene tablete su crvene, okrugle, bikonveksne tablete označene s BAYER- ovim križićem na jednoj strani, te brojem «15» i trokutom na drugoj strani.
Xarelto 15 mg film-coated tablets rivaroxaban
Xarelto 15 mg filmom obložene tablete rivaroksaban
Xarelto 15 mg film-coated tablets Xarelto 20 mg film-coated tablets rivaroxaban
Xarelto 15 mg filmom obložene tablete Xarelto 20 mg filmom obložene tablete rivaroksaban
Xarelto 15 mg tablets rivaroxaban
Xarelto 15 mg tablete rivaroksaban
Xarelto 15 mg tablets Xarelto 20 mg tablets rivaroxaban
Xarelto 15 mg tablete Xarelto 20 mg tablete rivaroksaban
Xarelto 2.5 mg film-coated tablets
Xarelto 2,5 mg filmom obložene tablete
Xarelto 2.5 mg film-coated tablets are light yellow, round, biconvex and marked with the BAYER- cross on one side and “2.5” and a triangle on the other side.
Xarelto 2,5 mg filmom obložene tablete su svijetložute, okrugle, bikonveksne tablete označene BAYER-ovim križićem na jednoj strani, te brojem "2,5" i trokutom na drugoj strani.
Xarelto 2.5 mg is contraindicated for the treatment of ACS in patients with a prior stroke or TIA (see section 4.3).
Xarelto 2,5 mg kontraindiciran je za liječenje akutnog koronarnog sindroma u bolesnika koji su imali moždani udar ili TIA (vidjeti dio 4.3).
Xarelto 2.5 mg, twice daily, N=5,114 n (%)
Xarelto 2,5 mg, dvaput na dan,
Xarelto 20 mg (only applicable for outer carton, not applicable for bottle label)
Xarelto 20 mg (primjenjivo samo za vanjsku kutiju, nije primjenjivo za etiketu za bocu)
Xarelto 20 mg film-coated tablets
Xarelto 20 mg filmom obložene tablete
Xarelto 20 mg film-coated tablets are brown-red, round, biconvex and marked with the BAYER-cross on one side and “20” and a triangle on the other.
Xarelto 20 mg filmom obložene tablete su smeđecrvene, okrugle, bikonveksne tablete označene s BAYER-ovim križićem na jednoj strani, te brojem «20» i trokutom na drugoj strani.
Xarelto 20 mg once daily was compared with placebo.
Terapija lijekom Xarelto od 20 mg jednom na dan uspoređena je s placebom.
Xarelto 20 mg tablets rivaroxaban
Xarelto 20 mg tablete rivaroksaban
Xarelto administration should be discontinued if severe haemorrhage occurs.
Primjena lijeka Xarelto mora se prekinuti ako se pojavi teško krvarenje.
Xarelto belongs to a group of medicines called antithrombotic agents.
Xarelto pripada grupi lijekova koji se nazivaju antitrombotici.
Xarelto can be taken with or without food (see sections 4.5 and 5.2).
Xarelto se može uzimati s hranom ili bez nje (vidjeti dijelove 4.5 i 5.2).
Xarelto contains lactose
Xarelto sadrži laktozu
Xarelto contains the active substance rivaroxaban and belongs to a group of medicines called antithrombotic agents.
Xarelto sadrži djelatnu tvar rivaroksaban i pripada skupinii lijekova koji se nazivaju antitromboticima.
Xarelto contains the active substance rivaroxaban and is used in adults to prevent blood clots in the veins after a hip or knee replacement operation.
Xarelto sadrži djelatnu tvar rivaroksaban i koristi se u odraslih za sprječavanje stvaranja krvnih ugrušaka u venama nakon operacije kojom se ugrađuje umjetni kuk ili umjetni koljeni zglob.
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).
Xarelto je kontraindiciran u bolesnika s bolešću jetre povezanom s koagulopatijom i klinički značajnim rizikom od krvarenja uključujući bolesnike s cirozom jetre, Child-Pugh stadija B i C (vidjeti dijelove 4.3 i 5.2).
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).
Xarelto je kontraindiciran u bolesnika s bolešću jetre povezanom s koagulopatijom i s klinički značajnim rizikom od krvarenja uključujući bolesnike s cirozom jetre, Child-Pugh stadija B i C (vidjeti dijelove 4.3. i 5.2.).
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).
Xarelto je kontraindiciran u bolesnika s bolešću jetre povezanom s koagulopatijom i s klinički značajnim rizikom od krvarenja, uključujući bolesnike s cirozom, Child-Pugh stadij B i C (vidjeti dio 4.3).
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).
Xarelto je kontraindiciran u bolesnika s bolešću jetre povezanom s koagulopatijom i s klinički značajnim rizikom od krvarenja, uključujući bolesnike s cirozom, Child-Pugh stadija B i C (vidjeti dio 4.3).
Xarelto is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Xarelto have not been established in these clinical situations.
Xarelto se ne preporučuje kao alternativa nefrakcioniranom heparinu u bolesnika s plućnom embolijom koji su hemodinamički nestabilni ili bi mogli dobiti trombolizu ili plućnu embolektomiju jer sigurnost i djelotvornost lijeka Xarelto u tim kliničkim situacijama nisu dokazani.
Xarelto is not recommended for people under 18 years of age.
Ne preporučuje se primjena lijeka Xarelto u osoba mlađih od 18 godina.
Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).
Xarelto se mora primjenjivati s oprezom u bolesnika s klirensom kreatinina 15 – 29 ml/min (vidjeti dio 4.4).
Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min.
Xarelto se mora primjenjivati oprezno u bolesnika s klirensom kreatinina od 15 - 29 ml/mm.
Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min.
Xarelto se mora primjenjivati s opreznom u bolesnika s klirensom kreatinina 15 – 29 ml/min.
Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min.
Xarelto se mora primjenjivati s oprezom u bolesnika s klirensom kreatinina 15 – 29 ml/min.
Xarelto must be taken exactly as prescribed by your doctor.
Xarelto morate uzimati točno prema uputama liječnika.
Xarelto should not be used in combination with certain other medicines which reduce blood clotting such as prasugrel or ticagrelor other than aspirin and clopidogrel/ticlopidine.
Xarelto se ne smije uzimati u kombinaciji s određenim drugim lijekovima koji smanjuju zgrušavanje krvi kao što su prasugrel ili tikagrelol, osim s acetilsalicilatnom kiselinom i klopidogrelom/tiklopidinom.
Xarelto thins the blood, which prevents you from getting dangerous blood clots.
Xarelto razrjeđuje krv i i tako Vas štiti od stvaranja opasnih krvnih ugrušaka.
Xarelto will not be given to you on its own.
Nećete dobivati samo Xarelto.
Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).
Xarelto, primijenjen istodobno samo s acetilsalicilatnom kiselinom (ASA) ili s ASA-om uz klopidogrel ili tiklopidin, je indiciran za prevenciju aterotrombotskih događaja u odraslih bolesnika nakon akutnog koronarnog sindroma s povišenim srčanim biomarkerima (vidjeti dijelove 4.3, 4.4 i 5.1).
Xelevia can be taken with or without food.
Xelevia se može uzimati s hranom ili bez nje.
Xeloda 150 mg film-coated tablets Capecitabine
Xeloda 150 mg filmom obložene tablete kapecitabin
Xeloda 150 mg film-coated tablets Xeloda 500 mg film-coated tablets capecitabine
Xeloda 150 mg filmom obložene tablete Xeloda 500 mg filmom obložene tablete kapecitabin
Xeloda 150 mg film-coated tablets.
Xeloda 150 mg filmom obložene tablete.
Xeloda 500 mg film-coated tablets
Xeloda 500 mg filmom obložene tablete
Xeloda 500 mg film-coated tablets Capecitabine
Xeloda 500 mg filmom obložene tablete kapecitabin
Xeloda can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Xeloda može potaknuti razvoj teških kožnih reakcija poput Stevens-Johnsonova sindroma i toksične epidermalne nekrolize.
Xeloda capecitabine
Xeloda kapecitabin
Xeloda dose calculations
Izračuni doze lijeka Xeloda
Xeloda has also been compared with the combination of 5-FU and folinic acid, both in combination with oxaliplatin (another cancer medicine), in two studies: the first involved 2,035 patients who had not been treated before, and the second involved 627 patients who had failed previous treatment with irinotecan and a fluoropyrimidine (a group of cancer medicines that includes 5-FU).
Lijek Xeloda je također uspoređen s kombinacijom 5-FU-a i folne kiseline, oboje u kombinaciji s oksaliplatinom (drugim antikarcenogenim lijekom), u dva ispitivanja: prvim je obuhvaćeno 2.035 bolesnika koji nisu prethodno liječeni, dok je drugim obuhvaćeno 627 bolesnika u kojih prethodna terapija irinotekanom i fluoropirimidinom (grupom antikarcinogenskih lijekova koja uključuje 5-FU) nije uspjela.
Xeloda is a cancer medicine that contains the active substance capecitabine.
Xeloda je lijek protiv raka koji sadrži djelatnu tvar kapecitabin.
Xeloda is indicated for the treatment of:
Xeloda je indicirana za liječenje:
Xeloda is not indicated in children and adolescents.
Xeloda nije namijenjena za primjenu u djece i adolescenata.
Xeloda is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient’s height and weight).
Xeloda se uzima dva puta dnevno u dozama između 625 i 1.250 mg po metru kvadratnom tjelesne površine (izračunato na temelju visine i težine bolesnika).
Xeloda is used to treat:
Ovaj se lijek primjenjuje u liječenju:
Xeloda is used with docetaxel (another cancer medicine) after treatment with anthracyclines (another type of cancer medicine) has failed.
Xeloda se primjenjuje u kombinaciji s docetakselom (drugim antikancerogenim lijekom) nakon neuspješne terapije antraciklinima (drugom vrstom antikancerogenog lijeka).
Xeloda is used with or without other cancer medicines in patients who have had surgery for ‘stage III’ or ‘Dukes’ stage C’ colon cancer; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Xeloda se primjenjuje u kombiniranoj terapiji s drugim antikancerogenim lijekovima ili kao monoterapija u bolesnika nakon operacije karcinoma debelog crijeva „stadija III” ili „stadija C” prema Dukesovoj klasifikaciji; metastaziranog kolorektalnog karcinoma (karcinoma debelog crijeva koji se proširio u ostale dijelove tijela).
Xeloda is used with or without other cancer medicines; advanced gastric (stomach) cancer.
Xeloda se primjenjuje s drugim antikancerogenim lijekovima ili kao monoterapija; uznapredovalog gastričnog karcinoma (karcinoma želuca).
Xeloda is used with other cancer medicines, including a platinum-containing cancer medicine such as cisplatin; locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Xeloda se primjenjuje u kombiniranoj terapiji s drugim antikancerogenim lijekovima, uključujući antikancerogene lijekove koji sadrže platinu, primjerice cisplatinom; lokalno uznapredovalog ili metastaziranog karcinoma dojke (karcinoma dojke koji se počeo širiti u druge dijelove tijela).
Xeloda must not be used in people who may be hypersensitive (allergic) to capecitabine, to any of the other ingredients, or to fluorouracil.
Xeloda se ne smije primjenjivati u osoba koje mogu biti preosjetljive (alergične) na kapecitabin, bilo koje druge pomoćne tvari ili fluorouracil.
Xeloda should only be prescribed by a doctor who is qualified in the use of cancer medicines.
Lijek Xeloda smije propisati samo liječnik koji je kvalificiran za uporabu antikancerogenih lijekova.
Xeloda should only be prescribed by a qualified physician experienced in the utilisation of anti- neoplastic medicinal products.
Lijek Xeloda može propisati samo liječnik specijalist s iskustvom u primjeni antineoplastičnih lijekova.
Xeloda tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken).
Xeloda tablete se preporučuje uzimati 14 dana, nakon čega slijedi 7 dana pauze (bez uzimanja tableta).
Xeloda tablets should be swallowed with water within 30 minutes after a meal.
Xeloda tablete moraju se progutati s vodom najkasnije 30 minuta nakon obroka.
Xeloda tablets should be swallowed with water within the 30 minutes after a meal.
Tablete Xeloda uzimaju se s vodom u roku od 30 minuta nakon obroka.
Xeloda with food and drink
Xeloda s hranom i pićem
XELOX showed a trend towards superior OS with a HR of 0.87 (95% CI=[0.72; 1.05]; p=0.1486) which translates into a 13% reduction in risk of death.
XELOX je pokazao trend prema poboljšanju ukupnog preživljenja uz omjer hazarda od 0,87 (95% CI=[0,72; 1,05]; p=0,1486), što znači 13%tno smanjenje rizika od smrti.
XELOX was demonstrated to be non-inferior to FOLFOX-4 in terms of progression-free survival in the per- protocol population and intent-to-treat population (see Table 9).
Rezultati su pokazali da XELOX protokol nije manje djelotvoran od FOLFOX-4 protokola u pogledu preživljenja bez progresije bolesti u populaciji po protokolu i populaciji bolesnika predviđenih za liječenje (vidjeti Tablicu 9).
XELOX+
XELOX i
Xenical 120 mg hard capsules
Xenical 120 mg tvrde kapsule
Xenical 120 mg hard capsules Orlistat
Xenical 120 mg tvrde kapsule orlistat
Xenical 120mg hard capsules
Xenical 120 mg tvrde kapsule orlistat
Xenical capsules are turquoise with the imprint “ROCHE XENICAL 120” and are supplied in blister packs and glass bottles, containing 21, 42 and 84 capsules.
Xenical kapsule tirkizne su boje s natpisom "ROCHE XENICAL 120", a dostupne su u blister pakiranjima i staklenim bocama sa 21,42 i 84 kapsule.